Uterine fibroids are a common condition that affects up to 80% of women in their lifetime. Nearly half of those women will experience symptoms that affect their quality of life and fertility, ...
Theramex has announced that the Scottish Medicine Consortium (SMC) has recommended Yselty® for the treatment of moderate to severe symptoms of uterine fibroids (UFs) aligned to the product indication ...
Theramex has announced that the Scottish Medicine Consortium (SMC) has recommended Yselty® for the treatment of moderate to severe symptoms of uterine fibroids (UFs) aligned to the product indication ...
A daily oral therapy for uterine fibroids has been recommended for NHS by NICE, providing a new option for around 30,000 women in England and Wales. Theramex's GnRH antagonist Yselty (linzagolix ...
Treatment varies with fibroid location and size ... more postoperative pain and longer recovery time. Both traditional and robot-assisted laparoscopy have similar pregnancy outcomes compared ...
Around 4,500 women in the UK will be eligible for treatment ... Uterine fibroids are benign tumours that develop in the womb, causing debilitating symptoms including heavy bleeding, pain and ...